17,720 Shares in CVS Health Corporation $CVS Acquired by Foster & Motley Inc.

Key Points

• Foster & Motley acquired 17,720 CVS Health shares in the second quarter, valued at approximately $1.83 million. Institutional investors collectively own 80.66% of the company.
• CVS reported strong quarterly results, with earnings of $2.58 per share and revenue of $106.10 billion, exceeding analyst estimates; revenue increased 7.3% year over year.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $107.17. CVS also pays a quarterly dividend of $0.665, representing a 2.8% annualized yield.

Foster & Motley Inc. acquired a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 17,720 shares of the pharmacy operator's stock, valued at approximately $1,833,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Handelsbanken Fonder AB increased its holdings in shares of CVS Health by 83.6% in the second quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator's stock worth $112,729,000 after purchasing an additional 496,124 shares during the period. State Street Corp boosted its stake in CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator's stock valued at $4,776,182,000 after buying an additional 1,245,457 shares during the period. Legal & General Group Plc grew its position in CVS Health by 0.3% during the fourth quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator's stock worth $738,777,000 after buying an additional 31,249 shares in the last quarter. Deutsche Bank AG increased its stake in CVS Health by 28.4% in the 4th quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator's stock worth $370,333,000 after acquiring an additional 1,031,998 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. bought a new position in CVS Health in the 4th quarter worth about $3,333,000. Institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

CVS stock opened at $93.58 on Thursday. The firm has a market cap of $119.68 billion, a P/E ratio of 24.76, a P/E/G ratio of 0.91 and a beta of 0.61. The firm's fifty day moving average is $102.32 and its 200 day moving average is $88.69. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. During the same period in the prior year, the business posted $1.81 EPS. CVS Health's quarterly revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Research analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health's dividend payout ratio (DPR) is presently 70.37%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CVS. Sanford C. Bernstein lifted their price target on CVS Health from $94.00 to $106.00 and gave the company an "outperform" rating in a research report on Tuesday, May 12th. Barclays raised their target price on shares of CVS Health from $106.00 to $108.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. UBS Group lifted their target price on shares of CVS Health from $122.00 to $126.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of CVS Health from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 5th. Finally, Cantor Fitzgerald increased their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Tuesday, July 7th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $107.17.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source